FDA Okays Vaccines for 2009 H1N1 Influenza Virus

CSL, MedImmune, Novartis, and Sanofi Pasteur will begin supply within the next four weeks. Sanofi's vaccine is indicated for children as young as six months.

Regulatory B Cells as Immunotherapy for Autoimmune Diseases

A rare type of B cell that naturally acts to dampen T cell immune responses could feasibly be exploited as a form of cell immunotherapy for autoimmune disorders, scientists report.

Novel Optical Imaging Method May Boost Structure-Guided Drug Design

Researchers from the Clemson University College of Science and the Heinrich Heine University in Germany have developed new optical imaging techniques that may accelerate the field of structural biology.

NEWS: Study Uncovers Mechanism of GPCR Signaling at the Trans-Golgi Network

New study data highlights how receptors for various drug therapies work inside cells.

Autism Symptoms Improved in Mice by Reducing Alzheimer’s Disease Protein

Studies in mouse models have shown how reducing levels of tau, a protein linked with Alzheimer’s disease, could prevent core symptoms of autism spectrum disorder. Tau has never before been linked with autism, but results from the newly reported studies, by a team at the Gladstone Institute of Neurological Disease, suggest that tau reduction holds promise as a potential treatment for some forms of autism.

Otsuka, Akebia Expand Vadadustat Development Deal to Europe and Beyond

Firms' existing deal for Phase III-stage CKD anemia drug in U.S. broadened to Europe, Canada, China, Russia, Australia, and the Middle East. Akebia will receive $73 million upfront, $135 million in development funding, and up to $657 million in milestones.

Gilead to Acquire Immunomedics for $21B, Adding Breast Cancer ADC to...

The acquisition will bring to Gilead TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) indicated for the treatment of adults with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.

GSK Confirms £500M Investment in Manufacturing Across Multiple U.K. Sites

Decision was prompted by news of tax break on profits from U.K.-owned IP.

Aratana Gains Access to Four Advaxis Immunotherapies for Companion Animal Use

Aratana, which is rapidly establishing itself as a leader in pet therapeutics, has obtained global rights to Advaxis’ ADXS-cHER2 for the treatment of osteosarcoma...

Large Tumors Destroyed by Innate/Adaptive Immunotherapy Combo

Combination cancer immunotherapy boosts the innate and adaptive immune responses to eradicate large, immunosuppressive tumors

Recently Featured

Scroll Up